Goldman Sachs Maintains Buy Rating on Abbott Laboratories (ABT) Stock

Abbott Laboratories (NYSE:ABT) is one of the Best Blue Chip Stocks Under $100 to Buy Now. On May 27, analyst David Roman from Goldman Sachs maintained a “Buy” rating on the company’s stock and reduced the price objective to $113.00 from $121.00. The analyst’s rating is supported by several factors that highlight improvements in fundamentals and an attractive risk-reward profile. Notably, the analyst pointed to the clear bridge from softer early-2026 trends to healthier growth later, thanks to the accelerated sales in Nutrition, Devices, and Diagnostics, and specific product ramps like Libre and new Electrophysiology launches.

Goldman Sachs Maintains Buy Rating on Abbott Laboratories (ABT) Stock

Furthermore, the analyst hinted at a visible path focused on margin expansion and earnings leverage in 2026 and beyond, amid potential improvement in sentiment as execution becomes evident. While the analyst acknowledged the challenges that Abbott Laboratories (NYSE:ABT) might face in the near-term, the current valuation remains compelling relative to the company’s growth profile. Also, optional catalysts, such as favorable reimbursement decisions and share repurchases, can result in further upside, added Roman.

Abbott Laboratories (NYSE:ABT) is engaged in discovering, developing, manufacturing, and selling health care products.

While we acknowledge the risk and potential of ABT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ABT and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best FMCG Stocks to Invest In According to Analysts and 11 Best Long-Term Tech Stocks to Buy According to Analysts.

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1